Spebrutinib

INN name:	Spebrutinib
Lab codes:	AVL-292, CC-292
Chemical name:	N-[3-({5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl}amino)phenyl]prop-2-enamide
Molecular formula:	C22H22FN5O3
Chemical Structure:	Add caption
CAS Registry Number:	1202757-89-8
Originator:	Avila Therapeutics
Developer:	Celgene Corporation
Class:	Antineoplastic
Mechanism of Action:	Tyrosine kinase inhibitor
WHO ATC code:	L01X-E (Protein kinase inhibitors) M01A (Antiinflammatory and Antirheumatic Products, Non-steroids)
EPhMRA code:	L1H (Protein Kinase Inhibitor Antineoplastics) M1A (Anti-Rheumatics, Non-Steroidal)
Clinical Trials: Conditions Phases Interventions Status Rheumatoid Arthritis Phase 2 Alone Recruiting Lymphoma, Large B-Cell, Diffuse Phase 1 Combination Recruiting Relapsed/Refractory B-cell Lymphoma Phase 1 Combination Active, not recruiting Healthy Volunteers Phase 1 Combination Completed Leukemia Lymphocytic Chronic B-Cell Phase 1 Combination Active, not recruiting Leukemia Lymphocytic Chronic B-Cell Phase 1 Combination Active, not recruiting B Cell Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia Phase 1 Alone Completed
Recent activities on the drug: